[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603724":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":40,"centralContacts":53,"locations":62,"responsibleParty":81,"collaborators":40,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":40,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":65,"whyStopped":40,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"University of Electronic Science and Technology of China","OTHER",[8,15,20,25,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Oxtocin 24IU group","EXPERIMENTAL","Interventions are placebo followed after 15 minutes by the lower does (24IU) oxytocin",[13,14],"Drug: Oxytocin lower does (24IU)","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"atosiban group","Interventions are placebo followed after 15 minutes by 150ug atosiban",[19,14],"Drug: Atosiban",{"label":21,"type":22,"description":23,"interventionNames":24},"placebo group","PLACEBO_COMPARATOR","Interventions are placebo followed after 15 minutes by another placebo",[14],{"label":26,"type":10,"description":27,"interventionNames":28},"Oxytocin 48IU group","Interventions are placebo followed after 15 minutes by the higher 48IU oxytocin does",[29,14],"Drug: Oxytocin higher does (48IU)",{"label":31,"type":10,"description":32,"interventionNames":33},"Atosiban and 24IU oxytocin group","Interventions are atosiban 150ug followed after 15 minutes by the lower (24IU) does of oxytocin",[13,19],[35,41,45,49],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","Oxytocin lower does (24IU)","Oxytocin (24IU) will be administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue)",[31,9],null,{"type":36,"name":42,"description":43,"armGroupLabels":44,"otherNames":40},"Oxytocin higher does (48IU)","Oxytocin (48IU) will be administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on and under the tongue)",[26],{"type":36,"name":46,"description":47,"armGroupLabels":48,"otherNames":40},"Atosiban","150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)",[31,16],{"type":36,"name":50,"description":51,"armGroupLabels":52,"otherNames":40},"Placebo","Placebo administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue). Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and the atosiban interventions.",[9,26,16,21],[54,59],{"name":55,"role":56,"phone":57,"phoneExt":40,"email":58},"Keith M Kendrick, PhD","CONTACT","+86-28-61830811","k.kendrick.uestc@gmail.com",{"name":60,"role":56,"phone":61,"phoneExt":40,"email":40},"Yige Wang, PhD","+86-13086688860",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":40,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"School of Life science and Technology, University of Electronic Science and Technology of China","RECRUITING","Chengdu","Sichuan","China","CN",{"type":71,"coordinates":72},"Point",[73,74],104.06667,30.66667,{"lat":74,"lon":73},[77],{"name":78,"role":56,"phone":79,"phoneExt":40,"email":80},"Yan Zhang, MSc","+86 18215678419","532769737@qq.com",{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"PRINCIPAL_INVESTIGATOR","Keith Kendrick","Professor","100603724","early-phase-1-the-effect-of-oral-oxytocin-and-atosiban-on-top-down-attention--otatosiban--100603724",false,"NCT07140237","The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )","The Influence and Regulatory Role of Exogenous and Endogenous Oxytocin on Top-down Attention in Humans","OTAtosiban","Inclusion Criteria:\n\n* Healthy male subjects without past or current psychiatric or neurological disorders\n\nExclusion Criteria:\n\n* History of or current neurological\u002Fpsychiatric disorders;\n* Use of psychotropic medications (including nicotine)\n* Visual impairments",true,"MALE","18 Years","35 Years",{"count":98,"type":99},250,"ESTIMATED","INTERVENTIONAL",[102],"EARLY_PHASE1","The main aim of the present study is to investigate whether orally (lingual spray) administered oxytocin influences human top-down attention via oxytocin receptors and whether its effects are dose- and task-dependent.",[105],"Healthy Adult Male",[107,108,46,109,110,111],"Oxytocin; Atosiban; Eye-tracking; Autistic trait","Oxytocin","Eye-tracking","Autistic trait","attention","2025-09-05",{"date":114,"type":115},"2025-09-08","ACTUAL",{"date":117,"type":99},"2025-09",{"date":119,"type":99},"2025-12-30",{"name":5,"class":6},1]